DK499086D0 - Konjugater af trichothecen og anvendelse af samme som terapeutisk substans - Google Patents

Konjugater af trichothecen og anvendelse af samme som terapeutisk substans

Info

Publication number
DK499086D0
DK499086D0 DK499086A DK499086A DK499086D0 DK 499086 D0 DK499086 D0 DK 499086D0 DK 499086 A DK499086 A DK 499086A DK 499086 A DK499086 A DK 499086A DK 499086 D0 DK499086 D0 DK 499086D0
Authority
DK
Denmark
Prior art keywords
conjugates
bonds
trichothecen
same
cells
Prior art date
Application number
DK499086A
Other languages
English (en)
Other versions
DK499086A (da
Inventor
Gowsala Pavanasasivam
Original Assignee
Neorx Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neorx Corp filed Critical Neorx Corp
Publication of DK499086D0 publication Critical patent/DK499086D0/da
Publication of DK499086A publication Critical patent/DK499086A/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
DK499086A 1985-10-17 1986-10-17 Konjugater af trichothecen og anvendelse af samme som terapeutisk substans DK499086A (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/788,325 US4744981A (en) 1985-10-17 1985-10-17 Trichothecene antibody conjugates

Publications (2)

Publication Number Publication Date
DK499086D0 true DK499086D0 (da) 1986-10-17
DK499086A DK499086A (da) 1987-04-18

Family

ID=25144143

Family Applications (1)

Application Number Title Priority Date Filing Date
DK499086A DK499086A (da) 1985-10-17 1986-10-17 Konjugater af trichothecen og anvendelse af samme som terapeutisk substans

Country Status (8)

Country Link
US (3) US4744981A (da)
EP (1) EP0220065B1 (da)
JP (1) JPH072651B2 (da)
CN (1) CN87104045A (da)
AT (1) ATE85758T1 (da)
DE (1) DE3687779T2 (da)
DK (1) DK499086A (da)
NO (1) NO864136L (da)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5405966A (en) * 1985-10-17 1995-04-11 Theodore; Louis J. Trichothecene conjugates
US4744981A (en) * 1985-10-17 1988-05-17 Neorx Corporation Trichothecene antibody conjugates
FR2601679B1 (fr) * 1986-07-15 1990-05-25 Sanofi Sa Immunotoxines, procede de preparation et compositions pharmaceutiques en contenant
FR2601680B1 (fr) * 1986-07-15 1990-06-29 Sanofi Sa Inhibiteur de la synthese proteique, procede d'isolement, utilisation et compositions pharmaceutiques en contenant
US5118612A (en) * 1987-04-28 1992-06-02 Wisconsin Alumni Research Foundation Assay for trichothecenes
US5030450A (en) * 1989-11-28 1991-07-09 Abbott Laboratories Method for inhibiting nematode infection of plants with Nematostatic trichothecene compositions
EP0510132B1 (en) * 1990-09-28 1997-05-14 Neorx Corporation Polymeric carriers for release of covalently linked agents
JPH04334377A (ja) * 1990-12-31 1992-11-20 Akzo Nv 酸−不安定性リンカー分子
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6663881B2 (en) 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
ATE485825T1 (de) 1993-01-28 2010-11-15 Boston Scient Ltd Therapeutische inhibitoren der zellen der glatten gefässmuskulatur
US20030083733A1 (en) * 1997-10-10 2003-05-01 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US20020091433A1 (en) * 1995-04-19 2002-07-11 Ni Ding Drug release coated stent
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US5837313A (en) * 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
ES2226120T3 (es) 1997-03-31 2005-03-16 Boston Scientific Limited Inhibidor terapeutico de celulas del musculo liso vascular.
EP1025212B1 (en) 1997-10-14 2007-09-26 Darwin Molecular Corporation Thymidine kinase mutants and fusion proteins having thymidine kinase and guanylate kinase activities
US7015244B1 (en) 1998-08-11 2006-03-21 Mark Zamoyski Inhalable chemical debridement for COPD
US20040039047A1 (en) 1998-08-11 2004-02-26 Mark Zamoyski Compositions and methods for treating lung cancers
IL143266A0 (en) 1998-11-27 2002-04-21 Darwin Discovery Ltd Transforming growth factor-beta binding proteins and pharmaceutical compositions for increasing bone mineral content utilizing the same
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
US6187203B1 (en) * 1998-12-01 2001-02-13 Academia Sinica Sample purification apparatus and method
US6911429B2 (en) * 1999-04-01 2005-06-28 Transition Therapeutics Inc. Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US6864235B1 (en) 1999-04-01 2005-03-08 Eva A. Turley Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US6355251B1 (en) 1999-06-15 2002-03-12 Mark Zamoyski Compositions and methods for epidermal chemexfoliation
US6346251B1 (en) 1999-06-15 2002-02-12 Mark Zamoyski Compositions and methods for treating psoriasis
US6468247B1 (en) 2000-04-21 2002-10-22 Mark Zamoyski Perfusion device for localized drug delivery
US6342520B1 (en) 2000-10-30 2002-01-29 Mark Zamoyski Locally injectable chemotherapeutics
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
DE60228477D1 (de) 2001-05-08 2008-10-02 Darwin Molecular Corp Verfahren zur regulierung der immunfunktion in primaten unter verwendung des foxp3-proteins
DE60234057D1 (de) 2001-07-25 2009-11-26 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
US6559178B1 (en) 2002-01-29 2003-05-06 Mark Zamoyski Compositions and methods for apoptotic chemosurgery
US20050026823A1 (en) * 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
EP1730174B1 (en) * 2004-03-05 2010-04-21 The Board Of Trustees Of The University Of Illinois Peptide carrier for drug delivery
AU2007207341B2 (en) 2006-01-20 2012-05-10 Women's & Children's Health Research Institute Incorporated Method of treatment, prophylaxis and diagnosis of pathologies of the bone
WO2008051285A2 (en) 2006-04-01 2008-05-02 Medical Service Consultation International, Llc Methods and compositions for detecting fungi and mycotoxins
TW200913987A (en) * 2007-09-20 2009-04-01 Golden Biotechnology Corp Extract of Myrothecium sp. mycelium used to inhibit growth of tumor cell
US20100068718A1 (en) 2008-08-22 2010-03-18 Hooper Dennis G Methods and Compositions for Identifying Yeast
US8962251B2 (en) 2009-10-08 2015-02-24 Medical Service Consultation International, Llc Methods and compositions for identifying sulfur and iron modifying bacteria
US8956821B2 (en) 2013-02-06 2015-02-17 Medical Service Consultation International, Llc Methods and compositions for detecting Aspergillus terreus, Aspergillus niger, and mycotoxins
CN104098740B (zh) * 2014-02-23 2016-01-20 江苏省农业科学院 一种单端孢霉烯族类毒素分子印迹聚合物
KR101680183B1 (ko) * 2014-12-04 2016-12-06 고려대학교 산학협력단 신규한 항바이러스용 조성물 및 이를 이용한 식물바이러스의 방제 방법
CN108822124B (zh) * 2018-06-12 2020-01-24 河北大学 一种单端孢霉烯族化合物及其制备方法和应用
CN108794502B (zh) * 2018-06-12 2021-02-05 宁波大学 一种单端孢霉烯类化合物及其制备方法和用途
CN110183462A (zh) * 2019-07-03 2019-08-30 中南大学湘雅医院 倍半萜烯类小分子化合物在制备治疗结肠癌药物、食品或保健品中的应用
CN111007244B (zh) * 2019-11-15 2021-10-08 中国农业科学院油料作物研究所 二乙酸镳草镰刀菌烯醇竞争型气压免疫传感器及检测方法
CN110806476B (zh) * 2019-11-15 2021-10-08 中国农业科学院油料作物研究所 检测二乙酰镳草镰刀菌烯醇污染的免疫层析试纸条、制备方法及其应用
CN110747172B (zh) * 2019-11-15 2021-07-20 中国农业科学院油料作物研究所 杂交瘤细胞株das5g11e7及其产生的抗二乙酸镳草镰刀菌烯醇单克隆抗体
WO2023137443A1 (en) 2022-01-14 2023-07-20 Regeneron Pharmaceuticals, Inc. Verrucarin a derivatives and antibody drug conjugates thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0044167A3 (en) * 1980-07-14 1982-04-21 The Regents Of The University Of California Antibody targeted cytotoxic agent
FR2504010B1 (fr) * 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
US4382952A (en) * 1981-05-19 1983-05-10 Warner-Lambert Company Antibiotic roridin L-2 and its use
JPS5843926A (ja) * 1981-09-08 1983-03-14 Suntory Ltd 選択性制癌剤
CA1203164A (en) * 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates
US4618585A (en) * 1982-03-18 1986-10-21 Board Of Regents, The University Of Texas System Hybridoma cell lines producing monoclonal antibodies directed against cervical cancer cells
JPS59116229A (ja) * 1982-12-24 1984-07-05 Teijin Ltd 細胞毒性複合体を活性成分とする癌治療用剤およびその製造法
US4624846A (en) * 1983-07-29 1986-11-25 Immunomedics, Inc. Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles
US4744981A (en) * 1985-10-17 1988-05-17 Neorx Corporation Trichothecene antibody conjugates
US5066789A (en) * 1988-09-30 1991-11-19 Neorx Corporation Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages

Also Published As

Publication number Publication date
US4906452A (en) 1990-03-06
JPS62181280A (ja) 1987-08-08
NO864136L (no) 1987-04-21
EP0220065A2 (en) 1987-04-29
EP0220065A3 (en) 1988-05-25
US4744981A (en) 1988-05-17
DK499086A (da) 1987-04-18
DE3687779D1 (de) 1993-03-25
ATE85758T1 (de) 1993-03-15
CN87104045A (zh) 1988-11-09
EP0220065B1 (en) 1993-02-17
DE3687779T2 (de) 1993-07-01
JPH072651B2 (ja) 1995-01-18
NO864136D0 (no) 1986-10-16
US5157104A (en) 1992-10-20

Similar Documents

Publication Publication Date Title
DK499086A (da) Konjugater af trichothecen og anvendelse af samme som terapeutisk substans
FI950062A (fi) Proteiinien foroaktivaatio konjugaatiotarkoituksia varten
AU563356B2 (en) Conjugate of enzyme and antibody
DE60039448D1 (de) Gegen das prostata-stammzellantigen (psca) gerichtete antikörper und deren verwendung
DE69129989T2 (de) Arzneimittelzusammensetzung zur behandlung oder vorbeugung maligner tumore
DE3686313D1 (de) Anti-immuntoxine gegen menschlichen eierstockkrebs und verfahren zu deren verwendung.
ATE124266T1 (de) Antikörper-konjugate mit zwei oder mehr kovalent vernetzten fc-regionen.
AU2709295A (en) Human monoclonal antibodies specific to cell cycle independent glioma surface antigen
ATE164838T1 (de) Neue propoxyphenderivate sowie deren protein-und polypeptidlabels und-konjugate
NZ221065A (en) Conjugates of antibodies and toxins with sulphur-containing linking groups
FI853389A0 (fi) Tumoerlaekemedel och foerfarande foer dess framstaellning.
ATE193534T1 (de) Benzodiazepin-derivate sowie deren konjugate mit proteinen und polypeptiden
AU584690B2 (en) E87ag antigen of pseudomonas aeruginosa, monoclonal antibody against it, and hybridoma
ATE76583T1 (de) Anti-immuntoxine gegen menschlichen eierstockkrebs und verfahren zu deren verwendung.
ATE97324T1 (de) Verwendung von amphipatischen molekuelen zur radiodarstellung und therapie mittels monoklonaler oder polyklonaler antikoerperkonjugate.
ATE178493T1 (de) Stabilisierte antikörperfragmente
NO951061L (no) Antistoffkonjugater med forbedrede egenskaper
TW221711B (en) N-AFP monoclonal antibody and method of preparation thereof

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment